AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Bertran-Alamillo, Jordi, Cattan, Valérie, Schoumacher, Marie, Codony-Servat, Jordi, Giménez-Capitán, Ana, Cantero, Frédérique, Burbridge, Mike, Rodríguez, Sonia, Teixidó, Cristina, Roman, Ruth, Castellví, Josep, García-Román, Silvia, Codony-Servat, Carles, Viteri, Santiago, Cardona, Andrés-Felipe, Karachaliou, Niki, Rosell, Rafael, Molina-Vila, Miguel-Angel
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6472415/
https://ncbi.nlm.nih.gov/pubmed/31000705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09734-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados